Drug Trial Radar · NCT07335211
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
206
Planned (sponsor's estimate)
Start
Jan 2026
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Huons Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Conditions
- Primary Open Angle Glaucoma (POAG)
- Ocular Hypertension
Interventions
HUC3-637Drug
Ophthalmic solution instilled directly into the eye (topical ocular administration)
HUC3-637-RDrug
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in diurnal IOPTime frame: 12 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk Samsung Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.